- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Algernon: Repurposing Established Drugs to Create New Treatments
Algernon Pharmaceuticals Inc. (CSE:AGN; OTCQB:AGNPF; XFRA:AGW) has launched its campaign on the Investing News Network’s life science channel.
Algernon Pharmaceuticals Inc. (CSE:AGN; OTCQB:AGNPF; XFRA:AGW) has launched its campaign on the Investing News Network’s life science channel.
Algernon is a clinical-stage pharmaceutical development company working to advance a portfolio of drugs targeting non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough.
By leveraging existing drugs and applying them to new treatments, Algernon is attempting to shorten the lengthy drug development process, which can take five or six years before being approved for human testing. Using a drug repurposing strategy, Algernon intends to rapidly advance its drugs into a Phase 2 clinical study quickly and efficiently while reducing safety concerns.
Algernon Pharmaceuticals’ company highlights include the following:
- Planning its first phase II trial for idiopathic pulmonary fibrosis and chronic cough in Q2 2020.
- Has a drug development program based on drug repurposing, which has a much lower risk of fail in human trials as a result of safety issues
- Reduced time and cost to move compounds into a phase II trial due to advancing safe, approved well established small molecules
- Company is advancing compounds that have matched or outperformed leading global treatments in animal studies
- Multi-billion dollar global markets for disease treatments
- Experienced management team and globally recognized medical advisory board
- Capital-efficient business model
Outlook Reports
Featured Stocks
Browse Companies
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 2330.16 | +13.87 | |
Silver | 27.43 | +0.25 | |
Copper | 4.57 | +0.08 | |
Oil | 82.88 | +0.07 | |
Heating Oil | 2.56 | 0.00 | |
Natural Gas | 1.63 | -0.03 |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.